Table 1–
Baseline patient characteristics for first-line treatment
| Treatment arm | ||||
|---|---|---|---|---|
| Temsirolimus (n = 35) |
Pazopanib (n = 34) |
|||
| Characteristic | No. | % | No. | % |
| Age (yr) | ||||
| Median | 61 | 61 | ||
| Range | 42–80 | 37–74 | ||
| Gender | ||||
| Female | 11 | 31.4 | 6 | 17.7 |
| Male | 24 | 68.6 | 28 | 82.3 |
| Ethnicity | ||||
| White | 27 | 77.1 | 26 | 76.5 |
| Hispanic | 5 | 14.3 | 3 | 8.8 |
| Other | 3 | 8.6 | 4 | 11.7 |
| ECOG PS | ||||
| 0 | 1 | 2.9 | 1 | 2.9 |
| 1 | 14 | 40.0 | 12 | 35.3 |
| 2 | 20 | 57.1 | 21 | 61.8 |
| Previous nephrectomy |
15 | 42.9 | 15 | 44.1 |
| Previous IL-2 | 2 | 5.7 | 1 | 2.9 |
| IMDC risk | ||||
| Intermediate | 11 | 31.4 | 8 | 23.5 |
| Poor | 24 | 68.6 | 26 | 76.5 |
ECOG PS = Eastern Cooperative Group performance status; IL-2 = interleukin-2; IMDC = International Metastatic Renal Cell Carcinoma Database Consortium.